BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Generex Biotechnology Corporation (OP: GNBT)
0.0364 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 8:10 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(GNBT) Community Analysis from
Bulls REASONS TO BUY
97%
agree
40 votes
Pain Free Insulin
0%
agree
0 votes
More to Love
50%
agree
2 votes
Massive Opportunity
Bears REASONS TO SELL
April 19, 2014
Stocks fell today as the economy added only 18,000 jobs in June, well below the 125,000 jobs analysts’ had expected. Job gains in May were also revised down to 25,000 from the initial...(read more)
(Benzinga, 10/11/10)
Generex Biotechnology Corporation (Nasdaq: GNBT) today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC. The closing of the transaction is subject to a number...(read more)
(Benzinga, 10/18/10)
Generex Biotechnology Corporation (Nasdaq: GNBT) announced today that Dr. Joseph Rubinfeld, an independent scientific advisor to the Company and a member of the Company's Scientific Advisory Board, issued the following statement in...(read more)
Generex Biotechnology (GNBT) Company Overview

There is no analysis for GNBT yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here